Under Therapeutic Pressure: ELCC Session Highlights How Tumor Switching is Reshaping the Treatment Landscape

… to develop complex resistance. Under therapeutic pressure, tumor evolution—or “switching”—can manifest in various ways, … transformation data and complex interpretation. “ctDNA is helpful if we witness systemic progression, …

Toward Durable Disease Control in EGFR-Mutant (mt) NSCLC: Interpreting the Survival Signals from FLAURA2 and MARIPOSA

… shifted from identifying the correct target to preventing tumor evolution beyond it. Two phase III trials—FLAURA2 and … with liver metastases, TP53 co-mutations, and detectable circulating tumor DNA (ctDNA). Toxicity differed from chemotherapy-based …

Phase II Trial Evaluates Amivantamab Plus Lazertinib in EGFR-Mutant Lung Cancers With New or Progressing Brain Metastases or Leptomeningeal Disease